Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).

Article  PubMed  Google Scholar 

Muggia, F. M., Blessing, J. A., Sorosky, J. & Reid, G. C. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 20, 2360–2364 (2002).

Article  CAS  PubMed  Google Scholar 

Garcia, A. A., Blessing, J. A., Nolte, S. & Mannel, R. S. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol. Oncol. 111, 22–26 (2008).

Article  CAS  PubMed  Google Scholar 

Miller, D. S., Blessing, J. A., Lentz, S. S. & Waggoner, S. E. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 87, 247–251 (2002).

Article  CAS  PubMed  Google Scholar 

Levine, D. A. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Le, D. T. et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiao, X., Melton, D. W. & Gourley, C. Mismatch repair deficiency in ovarian cancer—molecular characteristics and clinical implications. Gynecol. Oncol. 132, 506–512 (2014).

Article  CAS  PubMed  Google Scholar 

Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ott, P. A. et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J. Clin. Oncol. 35, 2535–2541 (2017).

Article  CAS  PubMed  Google Scholar 

Marcus, L., Lemery, S. J., Keegan, P. & Pazdur, R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin. Cancer Res. 25, 3753–3758 (2019).

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. Highlights of prescribing information: JEMPERLI. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf (2021).

Mirza, M. R. et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N. Engl. J. Med. 388, 2145–2158 (2023).

Article  CAS  PubMed  Google Scholar 

Eskander, R. N. et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N. Engl. J. Med. 388, 2159–2170 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manning-Geist, B. L. et al. Microsatellite instability–high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles. Clin. Cancer Res. 28, 4302–4311 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chow, R. D. et al. Distinct mechanisms of mismatch-repair deficiency delineate two modes of response to anti-PD-1 immunotherapy in endometrial carcinoma. Cancer Discov. 13, 312–331 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gulhan, D. C. et al. Genomic determinants of de novo resistance to immune checkpoint blockade in mismatch repair-deficient endometrial cancer. JCO Precis. Oncol. 4, 492–497 (2020).

Article  PubMed  Google Scholar 

Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847–856 (2015).

Article  CAS  PubMed  Google Scholar 

Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60–65 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270–274 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Middha, S. et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. JCO Precis. Oncol. 2017, PO.17.00084 (2017).

Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tan, W. C. C. et al. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun. (Lond.) 40, 135–153 (2020).

Article  PubMed  Google Scholar 

Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775–789 (2019).

Article  CAS  PubMed  Google Scholar 

Verma, V. et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat. Immunol. 20, 1231–1243 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Philip, M. & Schietinger, A. Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections. Curr. Opin. Immunol. 58, 98–103 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou, J. et al. Clinical significance of CD38 and CD101 expression in PD-1+CD8+ T cells in patients with epithelial ovarian cancer. Oncol. Lett. 20, 724–732 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Centofanti, E. et al. The spread of interferon-γ in melanomas is highly spatially confined, driving nongenetic variability in tumor cells. Proc. Natl Acad. Sci. USA 120, e2304190120 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

León-Castillo, A. et al. Interpretation of somatic POLE mutations in endometrial carcinoma. J. Pathol. 250, 323–335 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25–39 (2020).

Article  CAS  PubMed  Google Scholar 

Oaknin, A. et al. Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 6, 1766–1772 (2020).

Article  PubMed  Google Scholar 

Le, D. T. et al. PD-1 blockade in tumors with mismatch repair deficiency. J. Clin. Oncol. 33, https://doi.org/10.1200/jco.2015.33.18_suppl.lba100(2015).

Konstantinopoulos, P. A. et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J. Clin. Oncol. 37, 2786–2794 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353–1365 (2020).

Article  CAS  PubMed  Google Scholar 

Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500–2501 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Spouge, J. L. et al. Strong conformational propensities enhance T cell antigenicity. J. Immunol. 138, 204–212 (1987).

Article  CAS  PubMed  Google Scholar 

Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009–1021 (2017).

Article  CAS  PubMed  Google Scholar 

Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550 (2015).

Article  PubMed  Google Scholar